The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.
Hyperprolactinemia can be induced by dopamine D2 receptor-binding drugs such as antipsychotic drugs. The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. In this study, 27 acute psychotic inpatients completed a 12-week trial of risperidone. At baseline and at 2, 4, 8, and 12 weeks after beginning medication, the author measured PRL, assessed hyperprolactinemia-related symptoms, and administered the Brief Psychotic Rating Scale (BPRS). Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). The increases of PRL in females were higher than males. The changes in serum PRL levels were not significantly correlated with the improvements in total BPRS scores. PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. In conclusion, our study suggests that the changes in serum PRL levels were not significantly correlated with clinical efficacy of risperidone.
Lee
Bun-Hee
BH
Department of Psychiatry, Korea University Ansan Hospital, College of Medicine, 516 Go-Jan Dong, Ansan City, Kyunggi-Do 425-020, South Korea.
Kim
Yong-Ku
YK
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy*; D018967:Risperidone / Q000008:administration & dosage*; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone